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ABSTRACT
Fibromyalgia syndrome (FMS) is a common
chronic musculoskeletal pain disorder of
unknown etiology and characterized by
generalized body pain, hyperalgesia, and
other functional and emotional
comorbidities. Despite extensive research, no
treatment modality is effective for all FMS
patients. In this paper, we briefly review the
history of FMS and diagnostic criteria, and
potential pathophysiological mechanisms
including central pain modulation,
neurotransmitters, sympatho-adrenal and
hypothalamic–pituitary–adrenal systems and
peripheral muscle issues. The primary focus
of the paper is to review treatment options
for managing fibromyalgia symptoms. We
will discuss FDA-approved medications and
other pharmacologic agents, and non-
pharmacologic treatments that have shown
promising effects.
Keywords: Classification criteria; Duloxetine;
Fibromyalgia; Milnacipran; Non-pharmacologic
treatment; Pain; Pharmacologic treatment;
Pregabalin
INTRODUCTION
Fibromyalgia syndrome (FMS) is a prevalent
musculoskeletal pain disorder. The cardinal
features are generalized body pain and
hyperalgesic responses [1]. FMS patients
also commonly present a range of
functional disturbances, including persistent
fatigue, dysregulated sleep, cognitive
slowness, functional bowel disorder,
paresthesia, and mood disturbance [1]. An
earlier study [2] estimated the prevalence
rate at 3–5% in North America. The National
Arthritis Data Working group has estimated
that up to 5 million people in the US suffer
from FMS [3].
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History
FMS is not a new disorder. One of the earliest
descriptions can be found in the mid-ninth
century in Germany when a cluster of FMS
symptoms was collectively labeled as
‘‘Muskelschwiele’’ (muscle callus) and
considered as generalized body tenderness
with rheumatism [4]. The term ‘‘fibrositis’’
appeared in the early 1900s to describe
the condition, with inflammation of
the connective tissues assumed to be the
underlying pathophysiology [5]. The
assumption persisted until systematic
scientific studies began to appear in the
literature in the 1970s, when an underlying
inflammation was ruled out and a more
neutral term fibromyalgia proposed [6, 7].
Several criteria, based on common clinical
presentations, were delineated in the 1970s
and 1980s (e.g., [8, 9]), stimulating a
proliferation of research in the field.
However, these criteria were rarely applied
consistently and the lack of standardization
made integration of the study findings very
difficult.
Diagnostic Criteria
In the late 1980s, a multicenter study was
conducted with the intention of developing
empirically derived classification criteria for
FMS [1]. The study included approximately
300 patients with FMS and 285 controls with
other (non-FMS) painful conditions.
Comparison of a number of FMS-related
variables revealed two criteria with good
sensitivity and specificity that can differentiate
between the two groups. These criteria,
generally referred as the American College of
Rheumatology (ACR) criteria, consist of (1) a
history of widespread pain of 3 months or
longer duration and (2) presence of pain
responses at least 11 of 18 designated tender
points (TPs) [1].
Since publication in 1990, the ACR criteria
have become a standard in FMS research. They
have been used by the vast majority of
published reports on FMS to date, creating
some cohesiveness in the literature. However,
the ACR criteria are not free from criticisms.
One of the major issues is the validity of the TP
criterion; specifically, it is not clear what the
number of positive TPs actually measures. It is
possible that pain response to digital pressure to
the TPs may represent the underlying central
dysfunction of nociceptive processing, leading
to diffuse hyperalgesia. However, the number of
painful TPs has been found to be the parameter
most associated with psychological distress [10–
12], although pain sensitivity in the TPs seems
relatively independent of distress [11].
Furthermore, central sensitization is not FMS-
specific. Patients with various other chronic
pain states, including those with localized pain,
exhibit evidence that central sensitization plays
an important role in their disorder [13]. In
addition, there are a large number of individuals
who report chronic widespread pain (CWP)
without having 11 painful TPs, yet exhibit
clinical and functional presentations very
similar to FMS [14]. There is no clear
understanding of whether the presence of 11
or more TPs represents any clinical significance
or relevance to FMS. Altogether, the validity of
the TP count criterion is yet to be determined.
Another concern regarding the ACR criteria
is the lack of consideration of common
symptoms and dysfunctions. Chronic fatigue
and sleep problems are ubiquitous in FMS
patients; however, they were not included in
the ACR criteria because they are also
commonly experienced by other patients with
chronic pain and thus yielded unsatisfactory
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discriminability. However, those symptoms are
common enough to be characteristics of the
disorder yet not a part of the diagnostic criteria;
this is a stark contrast with other syndromes
such as depression where a diagnosis relies on
the presence of multiple common clinical
phenomena.
However, there is no question that the ACR
classification criteria provided much-needed
consistency in defining fibromyalgia for
research studies. Unfortunately, the clinical
utility of the ACR criteria is quite limited [15]
and the concordance between the ACR criteria
and clinical diagnosis is rather poor [16]. In
order to address these concerns, new diagnostic
criteria for FMS were proposed recently, based
on data from another multicenter study [17].
The new criteria involve the assessment by
clinicians of common symptoms such as
fatigue, unrefreshed wakening and cognitive
symptoms. The authors of the 2010 ACR criteria
specifically note that these new classification
criteria are not intended to replace the 1990
ACR classification criteria, but to be used as a
clinical tool in primary care and specialized
clinics. Eliminating the need to perform a
physical examination for the new criteria
would facilitate the use of the standardized
measure to diagnose fibromyalgia in clinical
settings. Furthermore, for certain research
studies, such as a large epidemiological project
where conducting TP examination is not
feasible, the new criteria will provide a degree
of standardization in the study samples. The
details of the ACR criteria are listed in Table 1.
Pathophysiology
The etiology of FMS is unknown. However,
accumulated evidence over the past 40 years
suggests that several factors potentially underlie
the disorder. Although the focus of this paper is
primarily on the management of FMS, we will
briefly review the literature, including the role
of central pain modulation processes, muscle
abnormality, neuroendocrine regulation, and
sleep.
Central Pain Modulation
Research has consistently shown that FMS is
associated with increased pain sensitivity that
suggests dysregulation of the pain modulation
process at the central level. As compared to
healthy subjects, FMS patients exhibit lower
pain thresholds to various types of
experimentally induced noxious stimuli [18–
21]. FMS is also associated with increased
windup (WU) sensitivity (heightened pain
perception when noxious stimuli are
repeatedly presented) [22]. Cortical activities
in response to noxious stimulation are
exaggerated in patients with FMS [19, 23, 24].
Neurotransmitters
Low levels of serotonin (5-hydroxytryptamine)
activity in FMS have been shown via decreased
plasma tryptophan [25], serum serotonin [26],
transfer ratio of tryptophan [27], and reuptake
site density [28]. Research also points to a
dysregulated dopaminergic system. FMS
patients show an augmented prolactin
response to a buspirone challenge test,
suggesting an increased sensitivity or density
of dopamine D2 receptors [29]. Positron
emission tomography L-DOPA uptake studies
also implicate disrupted presynaptic dopamine
activities [30].
Sympatho-Adrenal (SA) and Hypothalamic–
Pituitary–Adrenal (HPA) Systems
A large volume of evidence exists suggesting
that patients with FMS show hyporeactive SA
and HAP response to a wide range of stressors
including exercise [31, 32]. FMS is also
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associated with altered basal catecholamine
levels, independent of depression [33, 34], as
well as abnormal reactivity of the HPA, such as
abnormal adrenocorticotropic hormone
(ACTH) levels, hypoglycemia and blunted
cortisol response [35, 36]. Overall, these
studies suggest the presence of hyperactive
sympathetic activity with hyporeactive
response to stress [37–40]. Furthermore,
alteration of adrenergic gene polymorphisms
seems to be present in FMS patients [41, 42].
Research indicates that there is a specific
function-altering beta-adrenergic gene
polymorphism in FMS patients [43], and they
show a significant increase in gene expression of
adrenergic molecular receptors in response to
exercise, as well as at rest, as compared to
healthy controls [44, 45], implicating a genetic
vulnerability in at least some FMS patients.
Muscular Abnormalities and Peripheral Pain
Modulation
Although an early study found abnormal biopsy
results in the painful muscles in FMS patients
[46], the investigation of local muscle tissue has
yielded conflicting results. In general, evidence
supporting the microscopic evidence of
definitive pathology in the muscle tissues in
FMS is scarce [47]. However, a peripheral
abnormality, albeit limited, may contribute to
FMS pathophysiology. For example, affected
(i.e., painful) muscles of FMS patients show
hypoxia [48]. Some studies using P-31 magnetic
resonance spectroscopy [49, 50] have also
shown reduced levels of adenosine
triphosphate and phosphocreatine in FMS,
suggesting that these metabolic abnormalities
may contribute to muscle weakness and
fatigability in FMS. Decreased muscle blood
flow, as compared to healthy individuals, has
also been shown [51]. Problems with muscular
vasoconstriction (e.g., Raynaud’s syndrome) are
common in FMS [52]. These results suggest that
peripheral ischemia may contribute to muscle
pain. Furthermore, a significantly greater
number of active myofascial trigger points in
the trapezius muscles are found in FMS patients
relative to healthy people [53]. The number of
active trigger points seems to be related to
diffuse mechanical hyperalgesia in FMS [54],
suggesting that peripheral noxious inputs play a
critical role; peripheral abnormality may create
a biochemical environment that contributes to
local sensitization, leading to central pain
sensitivity [55].
TREATMENT OF FMS
Over the past four decades, a large variety of
modalities have been tested for treating FMS.
Overall, no single modality has been found to
be universally effective for all FMS patients, or
all FMS symptoms in an individual patient.
Below, we will review commonly used FMS
treatments as well as some treatments that have
attracted much public attention.
Pharmacologic Options
FDA-Approved Agents
There are three medications that were approved
by the federal drug administration (FDA) to
treat FMS. Pregabalin, a c-aminobutyric acid
(GABA) analog and antiepileptic agent, was the
first to be approved, in 2007. A multicenter,
double-blind, randomized controlled trial (RCT)
was conducted in 750 patients who were
randomized to receive pregabalin 300, 450 or
600 mg per day or placebo for 14 weeks;
significant improvement in pain and other
functional measures was achieved in all the
pregabalin groups as compared to the placebo
group [56]. A systematic review evaluating the
efficacy of pregabalin [57] found a benefit of
Pain Ther (2013) 2:87–104 91
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pregabalin relative to placebo in pain reduction,
improvement in sleep and quality of life
measures (except for mood variables). A
meta-analysis of 4 RCTs with more than 3,000
patients has shown that a 30% pain reduction
was reported by 40% of patients receiving
pregabalin versus 28% of those receiving
placebo [58].
One of the common criticisms of a
pharmacologic RCT is the lack of long-term
follow-ups. Recently, Arnold et al. [59]
published data from the open-label extension
studies from the pregabalin RCT with a total of
1,207 patients who were treated for up to a year,
in order to assess the long-term tolerability
profile and maintenance of pain reduction.
Approximately 81% of patients completed
treatment. On average, the pain reduction
observed in the RCT was maintained
throughout the treatment period and the
tolerability profile was comparable to that seen
in the RCT.
There are two other medications, both
serotonin norepinephrine reuptake inhibitors
(SNRIs), approved by the FDA to treat FMS.
Duloxetine was approved in 2008 and
milnacipran in 2009. Double-blind RCTs
evaluating duloxetine doses ranging between
60 and 120 mg per day have typically shown
greater improvement in pain reports and
self-report functioning than those in the
placebo arm [60–62]. Analysis of pooled data
from the 4 RCTs [63] indicates that 48% of
treated patients and 32% of patients receiving
placebo reported [30% pain reduction.
Secondary analyses have shown that
duloxetine was beneficial for reducing fatigue
in FMS [64]. An extension trial [65] of up to
1 year showed comparable tolerability and
maintenance of pain reduction. However, a
recent trial with duloxetine 30 mg failed to
show improvement in pain severity relative to
placebo, mostly due to the marked placebo
effects [66], consistent with the earlier finding
that 20 mg duloxetine did not improve pain
[62]. Similarly, double-blind RCTs [67–69]
evaluating milnacipran (100–200 mg daily)
showed significant improvement in pain
reports and a range of symptoms as compared
to placebo. Pooled data from 2 RCTs [70]
showed approximately 52–61% of treated
patients reporting [30% pain reduction, versus
36% of the placebo group. A recent update of
the 3-year open-label study [71] suggests that
the clinical benefit is sustained during the
long-term treatment.
A comparative evaluation of pregabalin,
milnacipran and duloxetine [72] showed similar
efficacy of the three drugs with regard to pain
reduction. However, there were some differences
in the secondary outcome measures and adverse
effects, suggesting that these differences may
guide a clinical decision as to which of these
agents to use for a particular patient.
One of the concerns with these trials is the
relatively high placebo response rates. For the
purpose of illustration, Fig. 1 shows the results
(% of patients reporting [30% pain reduction)
Fig. 1 Percentage of patients reporting [30% pain
reduction by dose for pregabalin [56], duloxetine [60],
and milnacipran [69] versus placebo. BID twice daily, QD
every day
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from the 3 trials [56, 60, 69] by dose. A recent
analysis [73] of data from 18 placebo-controlled
trials in over 3,500 patients estimates that
approximately 50% of treatment in response
to these drugs can be attributed to placebo
effects.
Other Pharmacologic Treatments
Sodium Oxybate Sodium oxybate is a
commercially produced form of the sodium
salt of c-hydroxybutyric acid (GHB). It has
been approved by the FDA to treat excessive
daytime sleepiness and cataplexy in
narcolepsy. The distinction between GHB and
sodium oxybate should be noted. GHB is a
Schedule I controlled substance due to the
high abuse potential whereas sodium oxybate
is Schedule III. Illicit GHB is said to produce
euphoric, aphrodisiac and relaxing effects [74]
and is considered one of the most popular
party drugs. It also causes amnesia and
increased passivity that has been used to aid
criminal activity (e.g., ‘‘date rape’’). However,
in general, the problems related to illicit GHB
have been declining significantly since the turn
of the century; nevertheless the risk associated
with the illicit GHB seems to greatly exceed
that of legally prescribed sodium oxybate [75].
Abuse and misuse complications of sodium
oxybate are relatively rare according to the post
marketing data [75, 76].
Its ability to restore slow wave sleep (SWS)
[77] has led to a series of trials to evaluate the
efficacy of sodium oxybate for treating FMS and
an application to the FDA. An early small,
crossover RCT [78] showed that sodium
oxybate 6 g a day at bedtime for 4 weeks
significantly improved pain, fatigue, and sleep
(restored SWS) as compared to placebo. More
recently, multicenter studies [79–81] have
shown that sodium oxybate 4.5–6 g per night
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FMS-related symptoms relative to placebo.
Table 2 [79–81] compares the percentage of
patients who reported [30% reduction in pain
and FMS symptoms (total scores from the
fibromyalgia impact questionnaire (FIQ) [82])
for sodium oxybate 4.5 and 6 g and placebo.
The outcomes for the two sodium oxybate doses
do not seem to differ. All studies found
relatively high placebo response rates. The
dropout rates were also relatively high due to
adverse effects, particularly for the higher dose
group (see Table 3 [79–81] for treatment
completion rates for each study). Another
concern regarding the use of sodium oxybate
is its very short elimination half-life of
approximately 30 min to 1 h [83]. For this
reason, the dose was divided into two half
doses, and the patients were required take a half
dose at bedtime and wake up 2.5–4 h after
bedtime to take another half dose. Interrupting
the sleep of patients with existing sleep
disturbance seems rather counterproductive
[84]. Nevertheless, a polysomnographic study
[85] demonstrated that sodium oxybate 6 g per
night in a divided dose led to a significant
improvement in the sleep measures in FMS,
including total sleep time, waking after sleep
onset, slow and wave sleep time.
The application for the FDA approval of
sodium oxybate for treating FMS was denied in
2010. The advisory committee [86] concluded
that the efficacy data, although promising, do
not show superior results to currently approved
medications. They also expressed significant
concern with the safety issues of the drug,
with a potential for abuse and misuse with
serious consequences. They felt that adequate
safety measures were not available at the time.
Tricyclics and Other Antidepressants Early
studies have shown that low dose
amitriptyline and cyclobenzaprine, two
tricyclic compounds, have beneficial effects on
FMS symptoms. A meta-analysis [87]
demonstrates that these agents help to reduce
pain, fatigue, and sleep disturbance in FMS.
However, there seems to be a large individual
variation in the treatment response, and it has
been estimated [88] that approximately 30% of
patients may benefit from tricyclics. The
introduction of selective serotonin reuptake
inhibitors (SSRIs) was received with much
enthusiasm as they were considered to be a
safer alternative to TCAs and could regulate
serotonin reuptake. However, the results from
RCTs were marginal for improving pain, sleep
and mood in FMS patients [89, 90], even with a
flexible dose [91].
Analgesics Corticosteroids were one of the
first classes of medications to be tested for
FMS; however, a double-blind RCT evaluating
prednisone showed no clinical benefit [92].
Common over-the-counter analgesics such as
non-steroidal anti-inflammatory drugs,
although widely used by FMS patients, also do
not appear to have any appreciable benefit [93].
The use of opioid analgesics in FMS does not
seem to be very common [94], and they are
generally not recommended for treating FMS,
due to the lack of demonstrated efficacy [95].
Tramadol with the combined actions of weak
opioid and norepinephrine and serotonin
reuptake inhibitor (SNRI) effects has shown
Table 3 Percentage of patients completing treatment in





Russell et al. [79] 81 88 67
Russell et al. [80] 61 65 57
Spaeth et al. [81] 70 65 61
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reduced pain and better functioning in a RCT
[96]. The results are promising but need to be
replicated.
Sedatives Benzodiazepine and non-
benzodiazepine hypnotics are commonly used
to treat FMS patients, often targeting sleep and
anxiety. However, controlled studies failed to
demonstrate significant benefit [93, 97]. It has
also to be argued that hypnotics/sedatives
should not be used chronically due to
potential complications and tolerance [98].
Dopamine Agonists There have been a few
small studies evaluating the efficacy of
dopamine agonists that are commonly used to
treat Parkinson’s disease and restless leg
syndrome. A double-blind RCT [99] testing
pramipexole for 14 weeks showed significant
improvement in FMS symptoms relative to
placebo. These preliminary results need to be
replicated in a larger trial.
Cannabinoids Cannabinoids have recently
emerged as an analgesic option for various
pain conditions. A synthetic cannabinoid
(nabilone) has been approved by the FDA for
use as a second-line treatment for
chemotherapy-induced nausea and vomiting.
An early retrospective chart review study [100]
of 20 patients with non-cancer chronic pain
found some improvement in pain and sleep,
suggesting a potential benefit for chronic pain
patients in general as an analgesic. In the first
double-blind RCT [101], 40 FMS patients
received either placebo or nabilone (titrated to
1 mg twice daily) for 4 weeks. The nabilone
group showed significant decrease in pain and
FIQ score relative to the placebo group at the
post-treatment assessment, although the
benefit seemed to disappear at the 8-week
follow-up. The nabilone group had a greater
dropout rate (25%) versus the placebo group
(10%) and reported more drowsiness (50%), dry
mouth (30%) and vertigo (27%). Ware et al.
[102] compared nabilone to amitriptyline in a
crossover trial where patients received a 2-week
trial of each drug with a 2-week washout in
between. Adverse effects (dizziness, nausea, dry
mouth, drowsiness) were more prominent with
nabilone. The two drugs showed a comparative
decrease in sleep disturbance, although it is not
clear whether there was a between-group
difference in the degree of benefit. The groups
did not differ with regard to the other FMS-
related symptoms, although it was not clear
whether they showed any improvement with
either treatment. Unfortunately, recruitment
was difficult, with approximately half of
patients who were approached declining to
participate, making it difficult to ascertain the
representability of the study sample. A
systematic review of cannabinoids for treating
non-cancer chronic pain [103] suggests that
they are safe and may have some modest benefit
for FMS, although the results are very
preliminary at this point. The issues of long-




Physical deconditioning is common in FMS
patients. Generally, incorporation of some
physical fitness program as a part of FMS
treatment is considered essential. The
literature indicates that the efficacy of exercise
seems to depend upon the content and
intensity of the program. Generally,
submaximal aerobic exercise, along with
strengthening and stretching elements, is
beneficial in reducing symptoms and
hyperalgesic response [104, 105]. At least a
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moderate level of exercise intensity seems to be
needed to derive clinical benefit but low
intensity exercise tends to yield limited benefit
[106]. Unfortunately, it is not easy to implement
relatively vigorous exercise for FMS patients,
as many patients are exercise-intolerant. The
general recommendations for providing exercise
therapy include (1) starting at a low level where
patients can engage without significant distress,
(2) gradual increase of the intensity level, (3)
incorporating different types of exercise, and (4)
reduction of exercise intensity/duration, while
maintaining the frequency of exercise, if not
tolerated [106, 107].
Behavioral/Complementary Modalities
Several behavioral modalities that are
commonly used to treat chronic pain patients
have been evaluated, although the
methodological constraints and variations
across studies make the quality of evidence
rather weak. Generally, inconsistent and
modest effects have been reported with
hypnosis and biofeedback [108, 109].
Mindfulness-based stress reduction (MBSR) is
an increasingly popular approach to treat
various chronic illnesses. For FMS, an early
study [110] showed some promising reduction
in pain and symptoms with MBSR training
relative to a control group. However, a
subsequent 3-arm study comparing MBSR
training to both active control (supportive
group with relaxation training) and wait list
group failed to show any benefit [111].
Complementary and alternative (CAM)
approaches are very popular with FMS
patients. Unfortunately, many of the trials are
not well-controlled or included small numbers
of patients. Because of the methodologic
concerns, the level of clinical benefit of CAM
therapies for FMS cannot be determined from
the current literature [112].
One of the most widely accepted behavioral
therapy modalities is cognitive-behavioral
therapy (CBT). Clinical trials testing CBT
alone, however, tend to be small with various
methodologic problems, making it difficult to
interpret its efficacy. In general, CBT
monotherapy is effective in improving the
target variables (e.g., maladaptive cognition,
mood, quality of life; QOL) [113–115]
although the effects on the primary FMS
symptoms may be limited. The efficacy seems
to improve when CBT is included as a part of a
multidisciplinary treatment program (see
below).
Multidisciplinary Treatment
Given the complex, multifactorial nature of
FMS, it is reasonable to assume that multimodal
therapy targeting multiple factors may work
well. However, systematic evaluation of studies
evaluating multidisciplinary therapy for FMS is
difficult because of the wide variability in the
parameters of the treatment. Unfortunately, the
lack of methodological vigor is not uncommon,
reflecting the difficulty of conducting costly,
logistically demanding trials using multimodal
approaches.
Although there are some other variations, a
typical trial testing a multidisciplinary approach
includes education, exercise and psychological
(typically cognitive behavioral) therapy.
Programs aimed at acquisition of coping and
pain management skills seem to provide better
results than those that mostly aim to provide
information/education [109]. A systematic
review [116] points to the methodological
weakness, yet provides some evidence of the
effectiveness of the approach for various
chronic pain conditions including FMS. The
effectiveness seems to last beyond the therapy;
reduction in pain and other symptoms was
observed 12 months later [117]. A recent
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recommendation [118] by FMS experts strongly
emphasizes the importance of educating
patients, establishing working goals, and
applying multimodal therapy approaches
consisting of education, medications, exercise
and CBT. There has only been one published
study thus far that specifically tested the
combination of CBT with medication [119]. In
this trial, patients were randomized to a
combination of CBT and milnacipran, drug
monotherapy or CBT alone. The results
suggest that the combination approach and
CBT monotherapy were equally beneficial in
reducing symptoms, i.e., milnacipran added
very little to the clinical benefit of CBT.
FUTURE DIRECTIONS
Despite extensive efforts to delineate an
effective treatment in the past 30 years, FMS
continues to be a very difficult chronic pain
condition to treat. Some prominent challenges
in interpreting the literature are the poor
quality of the methodology, particularly for
non-pharmacologic approaches, and the large
placebo effects in drug trials. Furthermore,
although clinical benefits are typically
evaluated by statistical comparisons of the
treatment groups, there remains a large
within-group variation in treatment response.
This makes it nearly impossible to know
whether a particular patient would benefit
from a certain treatment. Well-controlled
RCTs could indicate whether the treatment
would likely benefit an average patient, but
not a particular patient.
Recently, novel approaches have been
proposed to expand our ability to evaluate the
therapeutic effects for each patient. For example,
the new statistical framework, dynamically
modified outcomes (DYNAMO) [120] could
estimate the causal effects of therapy for each
patient and help determine the true effects of
therapy for a specific patient. The individually
customized statistical causal model can then
provide guidance for matching treatment to
patients. Similarly, the sequential multiple
assignment randomization trials (SMART) [121]
approach, in which patients undergo multiple
randomization to sequential treatments, may
provide adaptive analyses of efficacy at the
individual patient level that could help
establish the most effective clinical algorithm.
Given the heterogeneous treatment responses,
these approaches may greatly enhance the ability
to produce clinically significant and relevant
evidence in FMS clinical research.
The heterogeneity of FMS patients is not
limited to treatment response. A number of
reports note heterogeneity with respect to a
range of the disease parameters including
history and disease expression [122],
suggesting the importance of patient-centered,
individualized treatment planning. One of the
important, yet often neglected, aspects is the
variation in symptoms over time. Negative
mood/stress, poor sleep, and fatigue often
trigger an overall symptom exacerbation [123].
Daily longitudinal analyses of the symptom
fluctuation suggest that worsening in one
symptom often intensifies other symptoms,
although the degree to which one symptom
affects another varies across individuals [124].
In other words, although all symptoms
influence other symptoms to some level, each
person may have one symptom that exerts more
influence than others, presenting a unique
causal covariation pattern for this particular
patient. If we can identify which symptom
drives others in a patient, treatment certainly
can be customized to prioritize a particular
target symptom.
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Many clinical trials face the dilemma of
balancing the internal versus external validity.
Clearly, well-controlled studies are needed:
however, by making the study ‘‘clean’’ one
often creates an unrealistic clinical situation
where the results may not apply to the
population at large. In the real world, FMS
patients vary in a range of clinical variables with
often complicated issues such as mood disorders
and polypharmacy; however, in the current
clinical research environment, such
complication is not appreciated and is often
minimized by patient selection criteria. How we
can delineate an evidence-based approach that
is truly based on reality is a lingering question
with no easy answers. One approach may be to
test an agent/method of therapy to be
combined with another that has yielded
relatively good outcomes. For example, the
pharmacologic trials are mostly restricted to
testing the agents alone against placebo. Drugs
with promising results can be combined with
exercise or a multidisciplinary approach. The
recent study by Ang et al. [119] of a
combination of CBT and milnacipran is one of
the first published reports and more should be
done employing this type of approach. FMS
clinical research will require going beyond the
traditional RCT models and applying
innovative and novel conceptual and
methodologic ventures.
ACKNOWLEDGMENTS
No funding or sponsorship was received for this
study or publication of this article.
Dr. Okifuji is the guarantor for this article, and
takes responsibility for the integrity of the work
as a whole.
Conflict of interest. Dr. Okifuji and Dr. Hare
declare no conflicts of interest.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Wolfe F, Smythe HA, Yunus MB, Bennett RM,
Bombardier C, Goldenberg DL, et al. The
American college of rheumatology 1990 criteria
for the classification of fibromyalgia. Report of the
Multicenter Criteria Committee [see comments].
Arthr Rheum. 1990;33(2):160–72.
2. White KP, Speechley M, Harth M, Ostbye T. The
London fibromyalgia epidemiology study: direct
health care costs of fibromyalgia syndrome in
London. Canada. J Rheumatol. 1999;26(4):885–9.
3. Lawrence RC, Felson DT, Helmick CG, Arnold LM,
Choi H, Deyo RA, et al. Estimates of the prevalence
of arthritis and other rheumatic conditions in the
United States. Part II. Arthr Rheum. 2008;58(1):
26–35.
4. Simons DG. Muscle pain syndromes—Part I. Am J
Phys Med. 1975;54(6):289–311.
5. Gowers W. Lumbago: its lessons and analogues.
BMJ. 1904;1:117–21.
6. Bennett RM. Fibrositis: misnomer for a common
rheumatic disorder. West J Med. 1981;134(5):
405–13.
7. Yunus M, Masi AT, Calabro JJ, Miller KA,
Feigenbaum SL. Primary fibromyalgia (fibrositis):
clinical study of 50 patients with matched normal
controls. Semin Arthr Rheum. 1981;11(1):151–71.
8. Smythe H. Nonarticular rheumatism and the
fibrositis syndrome. In: Hollander L, editor.
Arthritis and allied conditions; a textbook of
rheumatology. 8th ed. Philadelphia: Lea & Febiger;
1972. p. 874–84.
9. Yunus MB, Masi AT, Aldag JC. Preliminary criteria
for primary fibromyalgia syndrome (PFS):
multivariate analysis of a consecutive series of PFS,
other pain patients, and normal subjects. Clin Exp
Rheumatol. 1989;7(1):63–9.
10. McCarberg B, Barkin RL, Wright JA, Cronan TA,
Groessl E, Schmidt SM. Tender points as predictors
of distress and the pharmacologic management of
98 Pain Ther (2013) 2:87–104
123
fibromyalgia syndrome. Am J Ther. 2003;10(3):
176–92.
11. Petzke F, Gracely RH, Park KM, Ambrose K, Clauw
DJ. What do tender points measure? Influence of
distress on 4 measures of tenderness. J Rheumatol.
2003;30(3):567–74.
12. Wolfe F. The relation between tender points and
fibromyalgia symptom variables: evidence that
fibromyalgia is not a discrete disorder in the
clinic. Ann Rheum Dis. 1997;56(4):268–71.
13. Woolf CJ. Central sensitization: implications for the
diagnosis and treatment of pain. Pain. 2011;152(3
Suppl):S2–15.
14. Clauw DJ, Crofford LJ. Chronic widespread pain
and fibromyalgia: what we know, and what we need
to know. Best Pract Res Clin Rheumatol. 2003;17(4):
685–701.
15. Fitzcharles MA, Boulos P. Inaccuracy in the diagnosis
of fibromyalgia syndrome: analysis of referrals.
Rheumatology (Oxford). 2003;42(2):263–7.
16. Katz RS, Wolfe F, Michaud K. Fibromyalgia
diagnosis: a comparison of clinical, survey, and
American college of rheumatology criteria. Arthr
Rheum. 2006;54(1):169–76.
17. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL,
Katz RS, Mease P, et al. The American college of
rheumatology preliminary diagnostic criteria for
fibromyalgia and measurement of symptom
severity. Arthr Care Res (Hoboken). 2010;62(5):
600–10.
18. Arroyo JF, Cohen ML. Abnormal responses to
electrocutaneous stimulation in fibromyalgia [see
comments]. J Rheumatol. 1993;20(11):1925–31.
19. Gibson SJ, Littlejohn GO, Gorman MM, Helme RD,
Granges G. Altered heat pain thresholds and
cerebral event-related potentials following painful
CO2 laser stimulation in subjects with fibromyalgia
syndrome. Pain. 1994;58(2):185–93.
20. Kosek E, Hansson P. Modulatory influence on
somatosensory perception from vibration and
heterotopic noxious conditioning stimulation
(HNCS) in fibromyalgia patients and healthy
subjects. Pain. 1997;70(1):41–51.
21. Petzke F, Clauw DJ, Ambrose K, Khine A, Gracely
RH. Increased pain sensitivity in fibromyalgia:
effects of stimulus type and mode of presentation.
Pain. 2003;105(3):403–13.
22. Staud R, Price DD, Robinson ME, Mauderli AP,
Vierck CJ. Maintenance of windup of second pain
requires less frequent stimulation in fibromyalgia
patients compared to normal controls. Pain.
2004;110(3):689–96.
23. Gracely RH, Petzke F, Wolf JM, Clauw DJ.
Functional magnetic resonance imaging evidence
of augmented pain processing in fibromyalgia.
Arthr Rheum. 2002;46(5):1333–43.
24. Lorenz J, Grasedyck K, Bromm B. Middle and long
latency somatosensory evoked potentials after
painful laser stimulation in patients with
fibromyalgia syndrome. Electroencephalogr Clin
Neurophysiol. 1996;100(2):165–8.
25. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC.
Plasma tryptophan and other amino acids in
primary fibromyalgia: a controlled study.
J Rheumatol. 1992;19(1):90–4.
26. Wolfe F, Russell IJ, Vipraio G, Ross K, Anderson J.
Serotonin levels, pain threshold, and fibromyalgia
symptoms in the general population. J Rheumatol.
1997;24(3):555–9.
27. Norregaard J, Bulow PM, Mehlsen J, Danneskiold-
Samsoe B. Biochemical changes in relation to a
maximal exercise test in patients with fibromyalgia.
Clin Physiol. 1994;14(2):159–67.
28. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM,
Javors MA, Bowden CA. Platelet 3H-imipramine
uptake receptor density and serum serotonin levels
in patients with fibromyalgia/fibrositis syndrome
[see comments]. J Rheumatol. 1992;19(1):104–9.
29. Malt EA, Olafsson S, Aakvaag A, Lund A, Ursin H.
Altered dopamine D2 receptor function in
fibromyalgia patients: a neuroendocrine study
with buspirone in women with fibromyalgia
compared to female population based controls.
J Affect Disord. 2003;75(1):77–82.
30. Wood PB, Patterson JC 2nd, Sunderland JJ, Tainter
KH, Glabus MF, Lilien DL. Reduced presynaptic
dopamine activity in fibromyalgia syndrome
demonstrated with positron emission tomography:
a pilot study. J Pain. 2007;8(1):51–8.
31. Kadetoff D, Kosek E. Evidence of reduced sympatho-
adrenal and hypothalamic–pituitary activity during
static muscular work in patients with fibromyalgia.
J Rehabil Med. 2010;42(8):765–72.
32. van Denderen JC, Boersma JW, Zeinstra P, Hollander
AP, van Neerbos BR. Physiological effects of
exhaustive physical exercise in primary fibromyalgia
syndrome (PFS): is PFS a disorder of neuroendocrine
reactivity? Scand J Rheumatol. 1992;21(1):35–7.
33. Loevinger BL, Muller D, Alonso C, Coe CL.
Metabolic syndrome in women with chronic pain.
Metabolism. 2007;56(1):87–93.
Pain Ther (2013) 2:87–104 99
123
34. Hamaty D, Valentine JL, Howard R, Howard CW,
Wakefield V, Patten MS. The plasma endorphin,
prostaglandin and catecholamine profile of patients
with fibrositis treated with cyclobenzaprine and
placebo: a 5-month study. J Rheumatol Suppl.
1989;19:164–8.
35. Adler GK, Kinsley BT, Hurwitz S, Mossey CJ,
Goldenberg DL. Reduced hypothalamic–pituitary
and sympathoadrenal responses to hypoglycemia in
women with fibromyalgia syndrome. Am J Med.
1999;106(5):534–43.
36. Crofford LJ, Pillemer SR, Kalogeras KT,
Cash JM, Michelson D, Kling MA, et al.
Hypothalamic–pituitary–adrenal axis perturbations
in patients with fibromyalgia. Arthr Rheum.
1994;37(11):1583–92.
37. Martinez-Lavin M. Biology and therapy of
fibromyalgia. Stress, the stress response system,
and fibromyalgia. Arthr Res Ther. 2007;9(4):216.
38. Di Franco M, Iannuccelli C, Valesini G.
Neuroendocrine immunology of fibromyalgia. Ann
N Y Acad Sci. 2010;1193:84–90.
39. Staud R. Heart rate variability as a biomarker of
fibromyalgia syndrome. Fut Rheumatol. 2008;3(5):
475–83.
40. Di Franco M, Iannuccelli C, Alessandri C, Paradiso
M, Riccieri V, Libri F, et al. Autonomic dysfunction
and neuropeptide Y in fibromyalgia. Clin Exp
Rheumatol. 2009;27(5 Suppl 56):S75–8.
41. Vargas-Alarcon G, Fragoso JM, Cruz-Robles D,
Vargas A, Martinez A, Lao-Villadoniga JI, et al.
Association of adrenergic receptor gene
polymorphisms with different fibromyalgia
syndrome domains. Arthr Rheum. 2009;60(7):
2169–73.
42. Light KC, White AT, Tadler S, Iacob E, Light AR.
Genetics and gene expression involving stress and
distress pathways in fibromyalgia with and without
comorbid chronic fatigue syndrome. Pain Res Treat.
2012;2012:1–13.
43. Xiao Y, He W, Russell IJ. Genetic polymorphisms of
the beta2-adrenergic receptor relate to guanosine
protein-coupled stimulator receptor dysfunction in
fibromyalgia syndrome. J Rheumatol. 2011;38(6):
1095–103.
44. Light AR, Bateman L, Jo D, Hughen RW,
Vanhaitsma TA, White AT, et al. Gene expression
alterations at baseline and following moderate
exercise in patients with chronic fatigue syndrome
and fibromyalgia syndrome. J Intern Med.
2012;271(1):64–81.
45. Light AR, White AT, Hughen RW, Light KC.
Moderate exercise increases expression for sensory,
adrenergic, and immune genes in chronic fatigue
syndrome patients but not in normal subjects.
J Pain. 2009;10(10):1099–112.
46. Bengtsson A, Henriksson KG, Larsson J. Muscle
biopsy in primary fibromyalgia. Light-microscopical
and histochemical findings. Scand J Rheumatol.
1986;15(1):1–6.
47. Drewes AM, Andreasen A, Schroder HD, Hogsaa B,
JennumP.Pathologyof skeletalmuscle infibromyalgia:
a histo-immuno-chemical and ultrastructural study. Br
J Rheumatol. 1993;32(6):479–83.
48. Bengtsson A, Henriksson KG. The muscle in
fibromyalgia—a review of Swedish studies.
J Rheumatol Suppl. 1989;19:144–9.
49. Park JH, Phothimat P, Oates CT, Hernanz-Schulman
M, Olsen NJ. Use of P-31 magnetic resonance
spectroscopy to detect metabolic abnormalities in
muscles of patients with fibromyalgia. Arthr
Rheum. 1998;41(3):406–13.
50. Sprott H, Rzanny R, Reichenbach JR, Kaiser WA, Hein
G, Stein G. 31P magnetic resonance spectroscopy in
fibromyalgic muscle. Rheumatology (Oxford).
2000;39(10):1121–5.
51. Elvin A, Siosteen AK, Nilsson A, Kosek E. Decreased
muscle blood flow in fibromyalgia patients during
standardised muscle exercise: a contrast media
enhanced colour Doppler study. Eur J Pain.
2006;10(2):137–44.
52. Bennett RM, Clark SR, Campbell SM, Ingram SB,
Burckhardt CS, Nelson DL, et al. Symptoms of
Raynaud’s syndrome in patients with fibromyalgia.
A study utilizing the Nielsen test, digital
photoplethysmography, and measurements of
platelet alpha 2-adrenergic receptors. Arthr
Rheum. 1991;34(3):264–9.
53. Ge HY, Nie H, Madeleine P, Danneskiold-Samsoe B,
Graven-Nielsen T, Arendt-Nielsen L. Contribution
of the local and referred pain from active myofascial
trigger points in fibromyalgia syndrome. Pain.
2009;147(1–3):233–40.
54. Alonso-Blanco C, Fernandez-de-las-Penas C,
Morales-Cabezas M, Zarco-Moreno P, Ge HY,
Florez-Garcia M. Multiple active myofascial trigger
points reproduce the overall spontaneous pain
pattern in women with fibromyalgia and are
related to widespread mechanical hypersensitivity.
Clin J Pain. 2011;27(5):405–13.
55. Staud R. Peripheral pain mechanisms in chronic
widespread pain. Best Pract Res Clin Rheumatol.
2011;25(2):155–64.
100 Pain Ther (2013) 2:87–104
123
56. Arnold LM, Russell IJ, Diri EW, Duan WR, Young
JP Jr, Sharma U, et al. A 14-week, randomized,
double-blinded, placebo-controlled monotherapy
trial of pregabalin in patients with fibromyalgia.
J Pain. 2008;9(9):792–805.
57. Hauser W, Bernardy K, Uceyler N, Sommer C.
Treatment of fibromyalgia syndrome with
gabapentin and pregabalin—a meta-analysis of
randomized controlled trials. Pain. 2009;145(1–2):
69–81.
58. Straube S, Derry S, Moore RA, McQuay HJ.
Pregabalin in fibromyalgia: meta-analysis of
efficacy and safety from company clinical trial
reports. Rheumatology (Oxford). 2010;49(4):
706–15.
59. Arnold LM, Emir B, Murphy TK, Zeiher BG, Pauer L,
Scott G, et al. Safety profile and tolerability of up to
1 year of pregabalin treatment in 3 open-label
extension studies in patients with fibromyalgia.
Clin Ther. 2012;34(5):1092–102.
60. Arnold LM, Rosen A, Pritchett YL, D’Souza DN,
Goldstein DJ, Iyengar S, et al. A randomized,
double-blind, placebo-controlled trial of
duloxetine in the treatment of women with
fibromyalgia with or without major depressive
disorder. Pain. 2005;119(1–3):5–15.
61. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke
MJ, Iyengar S, et al. A double-blind, multicenter
trial comparing duloxetine with placebo in the
treatment of fibromyalgia patients with or without
major depressive disorder. Arthr Rheum.
2004;50(9):2974–84.
62. Russell IJ, Mease PJ, Smith TR, Kajdasz DK,
Wohlreich MM, Detke MJ, et al. Efficacy and
safety of duloxetine for treatment of fibromyalgia
in patients with or without major depressive
disorder: results from a 6-month, randomized,
double-blind, placebo-controlled, fixed-dose trial.
Pain. 2008;136(3):432–44.
63. Arnold LM, Clauw DJ, Wohlreich MM, Wang F, Ahl
J, Gaynor PJ, et al. Efficacy of duloxetine in patients
with fibromyalgia: pooled analysis of 4 placebo-
controlled clinical trials. Prim Care Companion J
Clin Psychiatry. 2009;11(5):237–44.
64. Arnold LM, Wang F, Ahl J, Gaynor PJ, Wohlreich
MM. Improvement in multiple dimensions of
fatigue in patients with fibromyalgia treated with
duloxetine: secondary analysis of a randomized,
placebo-controlled trial. Arthr Res Ther.
2011;13(3):R86–93.
65. Mease PJ, Russell IJ, Kajdasz DK, Wiltse CG, Detke
MJ, Wohlreich MM, et al. Long-term safety,
tolerability, and efficacy of duloxetine in the
treatment of fibromyalgia. Semin Arthr Rheum.
2010;39(6):454–64.
66. Arnold LM, Zhang S, Pangallo BA. Efficacy and
safety of duloxetine 30 mg/d in patients with
fibromyalgia: a randomized, double-blind,
placebo-controlled study. Clin J Pain.
2012;28(9):775–81.
67. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao
SG. A double-blind placebo-controlled trial of
milnacipran in the treatment of fibromyalgia.
Hum Psychopharmacol. 2004;19(Suppl 1):S27–35.
68. Clauw DJ, Mease P, Palmer RH, Gendreau RM,
Wang Y. Milnacipran for the treatment of
fibromyalgia in adults: a 15-week, multicenter,
randomized, double-blind, placebo-controlled,
multiple-dose clinical trial. Clin Ther.
2008;30(11):1988–2004.
69. Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler
J, Chen W, et al. The efficacy and safety of
milnacipran for treatment of fibromyalgia. a
randomized, double-blind, placebo-controlled
trial. J Rheumatol. 2009;36(2):398–409.
70. Geisser ME, Palmer RH, Gendreau RM, Wang Y,
Clauw DJ. A pooled analysis of two randomized,
double-blind, placebo-controlled trials of
milnacipran monotherapy in the treatment of
fibromyalgia. Pain Pract. 2011;11(2):120–31.
71. Arnold LM, Palmer RH, Ma Y. A 3-year, open-label,
flexible-dosing study of milnacipran for the
treatment of fibromyalgia. Clin J Pain. 2013 [Epub
ahead of print].
72. Hauser W, Petzke F, Sommer C. Comparative
efficacy and harms of duloxetine, milnacipran,
and pregabalin in fibromyalgia syndrome. J Pain.
2010;11(6):505–21.
73. Hauser W, Sarzi-Puttini P, Tolle TR, Wolfe F. Placebo
and nocebo responses in randomised controlled
trials of drugs applying for approval for
fibromyalgia syndrome treatment: systematic
review and meta-analysis. Clin Exp Rheumatol.
2012;30(6 Suppl 74):78–87.
74. Barker JC, Harris SL, Dyer JE. Experiences of gamma
hydroxybutyrate (GHB) ingestion: a focus group
study. J Psychoactive Drugs. 2007;39(2):115–29.
75. Carter LP, Pardi D, Gorsline J, Griffiths RR. Illicit
gamma-hydroxybutyrate (GHB) and
pharmaceutical sodium oxybate (Xyrem):
differences in characteristics and misuse. Drug
Alcohol Depend. 2009;104(1–2):1–10.
76. Wang YG, Swick TJ, Carter LP, Thorpy MJ, Benowitz
NL. Sodium oxybate: updates and correction to
Pain Ther (2013) 2:87–104 101
123
previously published safety data. J Clin Sleep Med.
2011;7(4):415–6.
77. Pardi D, Black J. gamma-Hydroxybutyrate/sodium
oxybate: neurobiology, and impact on sleep and
wakefulness. CNS Drugs. 2006;20(12):993–1018.
78. Scharf MB, Baumann M, Berkowitz DV. The effects
of sodium oxybate on clinical symptoms and sleep
patterns in patients with fibromyalgia. J Rheumatol.
2003;30(5):1070–4.
79. Russell IJ, Perkins AT, Michalek JE. Sodium oxybate
relieves pain and improves function in fibromyalgia
syndrome: a randomized, double-blind, placebo-
controlled, multicenter clinical trial. Arthr Rheum.
2009;60(1):299–309.
80. Russell IJ, Holman AJ, Swick TJ, Alvarez-Horine
S, Wang YG, Guinta D. Sodium oxybate reduces
pain, fatigue, and sleep disturbance and
improves functionality in fibromyalgia: results
from a 14-week, randomized, double-blind,
placebo-controlled study. Pain. 2011;152(5):
1007–17.
81. Spaeth M, Bennett RM, Benson BA, Wang YG, Lai C,
Choy EH. Sodium oxybate therapy provides
multidimensional improvement in fibromyalgia:
results of an international phase 3 trial. Ann
Rheum Dis. 2012;71(6):935–42.
82. Burckhardt CS, Clark SR, Bennett RM. The
fibromyalgia impact questionnaire: development
and validation. J Rheumatol. 1991;18(5):728–33.
83. Food and Drug Administration. [cited 2013 04-03];
Xyrem (sodium oxybate)]. Available from: http://
www.fda.gov/ohrms/dockets/dockets/05n0479/05N-
0479-EC9-Attach-2.pdf.
84. Alarcon GS. Questioning the likelihood that sodium
oxybate can be used to successfully treat
fibromyalgia: comment on the article by Russell
et al. Arthr Rheum. 2009;60(9):2854.
85. Moldofsky H, Inhaber NH, Guinta DR, Alvarez-
Horine SB. Effects of sodium oxybate on sleep
physiology and sleep/wake-related symptoms in
patients with fibromyalgia syndrome: a double-
blind, randomized, placebo-controlled study.
J Rheumatol. 2010;37(10):2156–66.
86. Summary Minutes of the Joint Meeting of the
Arthritis Advisory Committee and the Drug Safety
and Risk Management Advisory Committee.
Bethesda: FDA. 2010.
87. Arnold LM, Keck PE Jr, Welge JA. Antidepressant
treatment of fibromyalgia. A meta-analysis and
review. Psychosomatics. 2000;41(2):104–13.
88. Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain
GA, Bykerk VP, et al. Comparison of amitriptyline,
cyclobenzaprine, and placebo in the treatment of
fibromyalgia. A randomized, double-blind clinical
trial [see comments]. Arthr Rheum.
1994;37(1):32–40.
89. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R,
Schmid C. A randomized, double-blind crossover
trial of fluoxetine and amitriptyline in the
treatment of fibromyalgia. Arthr Rheum.
1996;39(11):1852–9.
90. Wolfe F, Cathey MA, Hawley DJ. A double-blind
placebo controlled trial of fluoxetine in
fibromyalgia. Scand J Rheumatol. 1994;23(5):255–9.
91. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE,
Keck PE Jr. A randomized, placebo-controlled,
double-blind, flexible-dose study of fluoxetine in
the treatment of women with fibromyalgia. Am J
Med. 2002;112(3):191–7.
92. Clark S, Tindall E, Bennett RM. A double blind
crossover trial of prednisone versus placebo in the
treatment of fibrositis. J Rheumatol.
1985;12(5):980–3.
93. Russell IJ, Fletcher EM, Michalek JE, McBroom PC,
Hester GG. Treatment of primary fibrositis/
fibromyalgia syndrome with ibuprofen and
alprazolam. A double-blind, placebo-controlled
study. Arthr Rheum. 1991;34(5):552–60.
94. Mease PJ, Dundon K, Sarzi-Puttini P.
Pharmacotherapy of fibromyalgia. Best Pract Res
Clin Rheumatol. 2011;25(2):285–97.
95. Ngian GS, Guymer EK, Littlejohn GO. The use of
opioids in fibromyalgia. Int J Rheum Dis.
2011;14(1):6–11.
96. Bennett RM, Kamin M, Karim R, Rosenthal N.
Tramadol and acetaminophen combination tablets
in the treatment of fibromyalgia pain: a double-
blind, randomized, placebo-controlled study. Am J
Med. 2003;114(7):537–45.
97. Moldofsky H, Lue FA, Mously C, Roth-Schechter B,
Reynolds WJ. The effect of zolpidem in patients
with fibromyalgia: a dose ranging, double blind,
placebo controlled, modified crossover study.
J Rheumatol. 1996;23(3):529–33.
98. Clauw DJ. Pharmacotherapy for patients with
fibromyalgia. J Clin Psychiatry. 2008;69(Suppl
2):25–9.
99. Holman AJ, Myers RR. A randomized, double-blind,
placebo-controlled trial of pramipexole, a
dopamine agonist, in patients with fibromyalgia
102 Pain Ther (2013) 2:87–104
123
receiving concomitant medications. Arthr Rheum.
2005;52(8):2495–505.
100. Berlach DM, Shir Y, Ware MA. Experience with the
synthetic cannabinoid nabilone in chronic
noncancer pain. Pain Med. 2006;7(1):25–9.
101. Skrabek RQ, Galimova L, Ethans K, Perry D.
Nabilone for the treatment of pain in
fibromyalgia. J Pain. 2008;9(2):164–73.
102. Ware MA, Fitzcharles MA, Joseph L, Shir Y. The
effects of nabilone on sleep in fibromyalgia: results
of a randomized controlled trial. Anesth Analg.
2010;110(2):604–10.
103. Lynch ME, Campbell F. Cannabinoids for treatment
of chronic non-cancer pain; a systematic review of
randomized trials. Br J Clin Pharmacol.
2011;72(5):735–44.
104. Kelley GA, Kelley KS, Jones DL. Efficacy and
effectiveness of exercise on tender points in adults
with fibromyalgia: a meta-analysis of randomized
controlled trials. Arthritis. 2011;2011:125485.
105. Jones KD, Adams D, Winters-Stone K, Burckhardt
CS. A comprehensive review of 46 exercise
treatment studies in fibromyalgia (1988–2005).
Health Qual Life Outcomes. 2006;4:67.
106. Busch AJ, Webber SC, Brachaniec M, Bidonde J,
Bello-Haas VD, Danyliw AD, et al. Exercise therapy
for fibromyalgia. Curr Pain Headache Rep.
2011;15(5):358–67.
107. Jones KD, Burckhardt CS, Deodhar AA, Perrin NA,
Hanson GC, Bennett RM. A six-month randomized
controlled trial of exercise and pyridostigmine in
the treatment of fibromyalgia. Arthr Rheum.
2008;58(2):612–22.
108. Bernardy K, Fuber N, Klose P, Hauser W. Efficacy of
hypnosis/guided imagery in fibromyalgia
syndrome—a systematic review and meta-analysis
of controlled trials. BMC Musculoskelet Disord.
2011;12:133–43.
109. Okifuji A, Hare BD. Mangement of musculoskeletal
pain. In: Ebert MH, Kerns RD, editors. Behavioral
and Pharmacologic Pain Management: Cambridge:
Cambridge University Press; 2010.
110. Grossman P, Tiefenthaler-Gilmer U, Raysz A, Kesper
U. Mindfulness training as an intervention for
fibromyalgia: evidence of postintervention and
3-year follow-up benefits in well-being. Psychother
Psychosom. 2007;76(4):226–33.
111. Schmidt S, Grossman P, Schwarzer B, Jena S,
Naumann J, Walach H. Treating fibromyalgia with
mindfulness-based stress reduction: results from a
3-armed randomized controlled trial. Pain.
2011;152(2):361–9.
112. Adams N, Sim J. Rehabilitation approaches in
fibromyalgia. Disabil Rehabil. 2005;27(12):711–23.
113. Alda M, Luciano JV, Andres E, Serrano-Blanco A,
Rodero B, del Hoyo YL, et al. Effectiveness of
cognitive behaviour therapy for the treatment of
catastrophisation in patients with fibromyalgia: a
randomised controlled trial. Arthr Res Ther.
2011;13(5):R173–85.
114. Wicksell RK, Kemani M, Jensen K, Kosek E, Kadetoff
D, Sorjonen K, et al. Acceptance and commitment
therapy for fibromyalgia: a randomized controlled
trial. Eur J Pain. 2013;17(4):599–611.
115. Bernardy K, Fuber N, Kollner V, Hauser W. Efficacy
of cognitive-behavioral therapies in fibromyalgia
syndrome—a systematic review and metaanalysis of
randomized controlled trials. J Rheumatol.
2010;37(10):1991–2005.
116. Scascighini L, Toma V, Dober-Spielmann S, Sprott
H. Multidisciplinary treatment for chronic pain: a
systematic review of interventions and outcomes.
Rheumatology (Oxford). 2008;47(5):670–8.
117. Martin J, Torre F, Padierna A, Aguirre U, Gonzalez
N, Garcia S, et al. Six-and 12-month follow-up of an
interdisciplinary fibromyalgia treatment
programme: results of a randomised trial. Clin Exp
Rheumatol. 2012;30(6 Suppl 74):103–11.
118. Arnold LM, Clauw DJ, Dunegan LJ, Turk DC. A
framework for fibromyalgia management for
primary care providers. Mayo Clin Proc.
2012;87(5):488–96.
Pain Ther (2013) 2:87–104 103
123
119. Ang DC, Jensen MP, Steiner JL, Hilligoss J, Gracely
RH, Saha C. Combining cognitive-behavioral
therapy and milnacipran for fibromyalgia: a
feasibility randomized-controlled trial. Clin J Pain.
2013;29(9):747–54.
120. Donaldson GW, Nakamura Y, Moinpour C.
Mediators, moderators, and modulators of causal
effects in clinical trials—dynamically modified
outcomes (DYNAMO) in health-related quality of
life. Qual Life Res. 2009;18(2):137–45.
121. Almirall D, Compton SN, Gunlicks-Stoessel M,
Duan N, Murphy SA. Designing a pilot sequential
multiple assignment randomized trial for
developing an adaptive treatment strategy. Stat
Med. 2012;31(17):1887–902.
122. Wilson HD, Starz TW, Robinson JP, Turk DC.
Heterogeneity within the fibromyalgia population:
theoretical implications of variable tender point
severity ratings. J Rheumatol. 2009;36(12):2795–801.
123. Okifuji A, Turk DC. Stress and psychophysiological
dysregulation in patients with fibromyalgia syndrome.
Appl Psychophysiol Biofeedback. 2002;27(2):129–41.
124. Okifuji A, Bradshaw DH, Donaldson GW, Turk DC.
Sequential analyses of daily symptoms in women
with fibromyalgia syndrome. J Pain.
2011;12(1):84–93.
104 Pain Ther (2013) 2:87–104
123
